Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Jennifer L. Moseley"'
Autor:
Christos Fountzilas, Sukeshi Patel Arora, Bin Zhang, Pawel Kalinski, Gerard Nuovo, Matt Coffey, Karol Cheetham, Jennifer L. Moseley, Patrick Raber, Paul Fields, Kevin H. Eng, Grey A. Wilkinson, Devalingam Mahalingam
Purpose:Pelareorep is an intravenously delivered oncolytic reovirus that can induce a T-cell–inflamed phenotype in pancreatic ductal adenocarcinoma (PDAC). Tumor tissues from patients treated with pelareorep have shown reovirus replication, T-cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f4dedeec9062b92db0713dcae178df7
https://doi.org/10.1158/1078-0432.c.6529035.v1
https://doi.org/10.1158/1078-0432.c.6529035.v1
Autor:
Christos Fountzilas, Sukeshi Patel Arora, Bin Zhang, Pawel Kalinski, Gerard Nuovo, Matt Coffey, Karol Cheetham, Jennifer L. Moseley, Patrick Raber, Paul Fields, Kevin H. Eng, Grey A. Wilkinson, Devalingam Mahalingam
Supplementary Figures and Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b6fd348518376c084dd2d529e4dd590
https://doi.org/10.1158/1078-0432.22475292.v1
https://doi.org/10.1158/1078-0432.22475292.v1
Autor:
Pawel Kalinski, Gerard J. Nuovo, Jennifer L. Moseley, Matthew C. Coffey, Devalingam Mahalingam, Paul Fields, Karol Cheetham, Christos Fountzilas, Sukeshi Patel Arora, Grey A. Wilkinson, Kevin H. Eng, Bin Zhang, Patrick Raber
Publikováno v:
Clinical Cancer Research. 26:71-81
Purpose:Pelareorep is an intravenously delivered oncolytic reovirus that can induce a T-cell–inflamed phenotype in pancreatic ductal adenocarcinoma (PDAC). Tumor tissues from patients treated with pelareorep have shown reovirus replication, T-cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2eb9fbf91d3f63d43d7ba45067e7aee
https://doi.org/10.1158/1078-0432.ccr-19-2078
https://doi.org/10.1158/1078-0432.ccr-19-2078
Autor:
Giovanni Selvaggi, Matthew C. Coffey, Nicole Noronha, John Sarantopoulos, Jennifer L. Moseley, Romit Chakrabarty, Hue Tran, Devalingam Mahalingam, Christos Fountzilas, Brad Thompson
Publikováno v:
Cancer Chemotherapy and Pharmacology. 79:697-703
REOLYSIN® (pelareorep) is an investigational new drug, consisting of a live, replication-competent, Reovirus Type 3 Dearing strain in a proprietary formulation. Several preclinical and clinical trials with REOLYSIN® on a wide range of cancer indica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce3aa7f53c7c00aa1d98b753b9a43928
https://doi.org/10.1007/s00280-017-3260-6
https://doi.org/10.1007/s00280-017-3260-6
Autor:
Alex R. Lane, Claudine Wack, Alain C. Mita, Laurent Kassalow, Stephanie L. Barber, Jean François Dedieu, Andrea Wang-Gillam, Jennifer L. Moseley, Monica M. Mita, A. Craig Lockhart, John Sarantopoulos, Shankar Sundaram
Publikováno v:
Investigational New Drugs. 32:1236-1245
Introduction Cabazitaxel is a second-generation taxane with in vivo activity against taxane-sensitive and -resistant tumor cell lines and tumor xenografts. Cabazitaxel/cisplatin have therapeutic synergism in tumor-bearing mice, providing a rationale
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7180585963ad6fbf190331d0d1323040
https://doi.org/10.1007/s10637-014-0145-y
https://doi.org/10.1007/s10637-014-0145-y
Autor:
Devalingam Mahalingam, Christos Fountzilas, Jennifer L. Moseley, Nicole Noronha, Karol Cheetham, Adrian Dzugalo, Gerard Nuovo, Andres Gutierrez, Sukeshi Patel Arora
Publikováno v:
Journal of Clinical Oncology. 36:283-283
283 Background: Pelareorep (REOLYSIN) is a immuno-oncolytic virus (IOV) that induces an inflamed tumor phenotype secondary to viral infection of cancer cells. In combination with chemotherapy, it achieves 1 & 2 year-survival rates of 46% & 24% in MAP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac231661c1283d2d86036524dba77510
https://doi.org/10.1200/jco.2018.36.4_suppl.283
https://doi.org/10.1200/jco.2018.36.4_suppl.283
Autor:
Florent Mazuir, John Sarantopoulos, Benjamin R. Tan, Xin Zhi, Alex R. Lane, Jennifer L. Moseley, Jean-Francois Dedieu, Diane Stash, Albert C. Lockhart, Shankar Sundaram, Monica M. Mita, Devalingam Mahalingam, Alain C. Mita
Publikováno v:
Journal of Clinical Oncology. 30:e15116-e15116
e15116 Background: Cabazitaxel (Cbz) is a novel taxane with in vivo efficacy in taxane-sensitive and -resistant tumors. Therapeutic synergism of Cbz/cisplatin (Cis) has been shown in tumor-bearing mice. Since Cbz is primarily metabolized by CYP3A, dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6eadcd09da0215e1accf19e4b515f8ea
https://doi.org/10.1200/jco.2012.30.15_suppl.e15116
https://doi.org/10.1200/jco.2012.30.15_suppl.e15116
Autor:
Albert C. Lockhart, Jennifer L. Moseley, Diane Stash, Jean-Francois Dedieu, Alex R. Lane, Xin Zhi, Monica M. Mita, Shankar Sundaram, Alain C. Mita, Florent Mazuir, John Sarantopoulos
Publikováno v:
Journal of Clinical Oncology. 30:162-162
162 Background: Cabazitaxel (Cbz) is a novel taxane with broad in vivo efficacy in taxane-sensitive and -resistant tumors. Clinical activity of Cbz was confirmed in the Phase III TROPIC trial ( NCT00417079 ); Cbz significantly improved overall surviv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18b4c1c45bd82ab186b2e9545575ae44
https://doi.org/10.1200/jco.2012.30.5_suppl.162
https://doi.org/10.1200/jco.2012.30.5_suppl.162
Autor:
Geoffrey I. Shapiro, J. Poon, Jennifer L. Moseley, Alain C. Mita, Paul Statkevich, Rajat Bannerji, Scott J. Rodig, K. K. Sankhala, Y. Jou, John Sarantopoulos, Karen Small, Monica M. Mita, P. Kirschmeier, James M. Cleary, D. Zhang, Lucian R. Chirieac
Publikováno v:
Journal of Clinical Oncology. 29:3080-3080
3080 Background: Dinaciclib is a potent and selective inhibitor of CDKs 1, 2, 5, and 9 with anti-tumor activity in multiple tumor cell lines and xenograft models. Methods: Dinaciclib is administere...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::044c9594facb04d4968cf102dc38e1a9
https://doi.org/10.1200/jco.2011.29.15_suppl.3080
https://doi.org/10.1200/jco.2011.29.15_suppl.3080
Autor:
Stephen L. Warren, Rajat Bannerji, Paul Statkevich, Mark Navarro, Charles L. Shapiro, Siu-Long Yao, Jennifer L. Moseley, Anil A. Joy, Alain C. Mita, Ying-Ming Jou, Kamalesh Kumar Sankhala, Da Zhang, Monica M. Mita
Publikováno v:
Cancer Research. 71:4718-4718
Dinaciclib is a potent, selective inhibitor of CDKs 1, 2, 5, and 9 with preclinical activity in breast cancer cell lines and tumor xenografts. A randomized, multicenter, open-label phase 2 study was conducted to compare the efficacy of dinaciclib and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0d447b4e5620e44e3a15bf04b17cf81
https://doi.org/10.1158/1538-7445.am2011-4718
https://doi.org/10.1158/1538-7445.am2011-4718